Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $1.48 Analyst target: $4.00 Upside: 170.27%
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of cell therapy, and for other adoptive cell therapies. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.